ALS Recent Progress Evaluation at MDA 2023.

Published Date: 01 Mar 2023

In the MDA session track on amyotrophic lateral sclerosis, Stanley Appel, MD, provided his perspective on the condition, the most recent scientific developments that will benefit patients, and the direction that research and treatment in the area are taking.

Read Full News

Latest News

AbbVie's Menstrual Migraine Treatment Meets Late-stage Study Goal

AbbVie said on Thursday its migraine treatment had in ⁠a late-stage study reduced the migraine days associated with the ⁠menstrual period.

US FDA Pauses New Enrollment in Biohaven's Epilepsy Drug Trials

Biohaven said on Thursday the U.S. FDA had imposed a partial clinical hold, pausing new patient enrollment in trials ⁠of its experimental epilepsy drug after rodent...

Tylenol Use in Pregnancy May Be Linked With Uterus, Ovary Changes in Daughters

Female reproductive organ development may be impacted by a mother's use during pregnancy of Tylenol or its generic versions, according to researchers who emphasize that...

Ionis Pharma Prices First FDA-approved Treatment for Alexander Disease At $285,000 Per Dose

Ionis Pharmaceuticals said on Friday it would price its newly approved therapy ⁠to treat Alexander disease at $285,000 per dose, a day after the U.S. FDA cleared the...

New Migraine Prevention Guidelines Released

Updated migraine prevention guidelines recommend preventive treatment for patients with ≥ 4 migraine days per month and incorporate CGRP-targeted therapies into individualized treatment selection.

Novartis Pauses Trials Of Experimental Cell Therapy After Three Deaths

Novartis said on Tuesday it paused eight clinical trials of an experimental cell therapy, called rap-cel, targeting autoimmune and neurological disorders in late ⁠August,...

Todays Updates

First-Line T-DXd Boosts PFS in HER2-Mutant NSCLC

DESTINY-Lung04 supports trastuzumab deruxtecan as a new frontline option for patients with advanced HER2-mutant disease, though it failed to improve overall survival.

Could Burnout Become the Employer’s Responsibility?

A European Parliament committee is backing employer risk assessments to tackle burnout. But should that mean new binding EU rules?

High CLL Remission Seen With First-Line Triplet Regimen

High 2-year survival rates are seen in treatment-naive patients with CLL receiving a noncovalent BTK inhibitor combined with venetoclax and obinutuzumab.

FET-PET Agent Approved for Glioma Imaging

Floretyrosine F18 is the first amino acid PET imaging agent approved for glioma in the United States.

Todays Updates

First-Line T-DXd Boosts PFS in HER2-Mutant NSCLC

DESTINY-Lung04 supports trastuzumab deruxtecan as a new frontline option for patients with advanced HER2-mutant disease, though it failed to improve overall survival.

Could Burnout Become the Employer’s Responsibility?

A European Parliament committee is backing employer risk assessments to tackle burnout. But should that mean new binding EU rules?

High CLL Remission Seen With First-Line Triplet Regimen

High 2-year survival rates are seen in treatment-naive patients with CLL receiving a noncovalent BTK inhibitor combined with venetoclax and obinutuzumab.

FET-PET Agent Approved for Glioma Imaging

Floretyrosine F18 is the first amino acid PET imaging agent approved for glioma in the United States.

Latest News

AbbVie said on Thursday its migraine treatment had in ⁠a late-stage study reduced the migraine days associated with the ⁠menstrual period.

Biohaven said on Thursday the U.S. FDA had imposed a partial clinical hold, pausing new patient enrollment in trials ⁠of its experimental epilepsy drug after rodent...

Female reproductive organ development may be impacted by a mother's use during pregnancy of Tylenol or its generic versions, according to researchers who emphasize that...

Ionis Pharmaceuticals said on Friday it would price its newly approved therapy ⁠to treat Alexander disease at $285,000 per dose, a day after the U.S. FDA cleared the...

Updated migraine prevention guidelines recommend preventive treatment for patients with ≥ 4 migraine days per month and incorporate CGRP-targeted therapies into individualized treatment selection.

Novartis said on Tuesday it paused eight clinical trials of an experimental cell therapy, called rap-cel, targeting autoimmune and neurological disorders in late ⁠August,...

News All Time

The New Standard in Multiple Sclerosis: Integrating Evolving Treatment Evidence and Biomarkers to Target Progression

The New Standard in Multiple Sclerosis: Integrating Evolving Treatment Evidence and Biomarkers to Target Progression

Navigating Diagnostic Complexity in Leptomeningeal Metastases: Real-World Case Challenges in Timely Diagnosis of Leptomeningeal Metastases

Navigating Diagnostic Complexity in Leptomeningeal Metastases: Real-World Case Challenges in Timely Diagnosis of Leptomeningeal Metastases

Dravet Syndrome Clinical Pearls: Uncovering Disease Impact and Partnering With Patients and Caregivers to Individualize Treatment Plans

Dravet Syndrome Clinical Pearls: Uncovering Disease Impact and Partnering With Patients and Caregivers to Individualize Treatment Plans

Leptomeningeal Metastases: Early Recognition, Diagnosis, and Multidisciplinary Care

Leptomeningeal Metastases: Early Recognition, Diagnosis, and Multidisciplinary Care

Decoding Leptomeningeal Metastases: Strategies for Early Detection and Accurate Diagnosis

Decoding Leptomeningeal Metastases: Strategies for Early Detection and Accurate Diagnosis

Superagers' Exceptional Memory Can't Be Explained by Genes Alone, Study Finds

Inherited Alzheimer's risk didn't differ between superagers and cognitively average older adults

Diarrhea Bug Outbreak Hits 4 More States; Fauci to Testify; Doc Dies in House Fire

Health news and commentary gathered by MedPage Today staff

Hold Off on JAK Inhibitors in Rheumatoid Arthritis Until After Shingles Vax?

Good things come to those who wait -- and to those who don't wait

FDA Approves Tylenol With Naproxen Combination

First OTC fixed-dose combination product to pair acetaminophen with naproxen sodium

FDA Panel Finds a Peptide It Doesn't Like

Over 2-day meeting, six of seven peptides are recommended for adding to bulk compounding list

Brain Worm Culprit in Woman's Hallucinations, Incoherent Speech

MRI uncovers neurocysticercosis in a 52-year-old woman

First-in-Class Drug for ADHD Wins FDA Approval

Triple reuptake inhibitor centanafadine is indicated for patients ages 6 years and older

FDA Scientists Raise Questions About Duchenne Drug

Agency says deramiocel did not meet phase III trial endpoints, contrary to reported data

Feds Delay Autism Meeting; Wildfire Smoke and Migraine; Mortality and MS

News and commentary from the world of neurology and neuroscience

Sugar Rationing in Early Life Linked to Lower Dementia Risk Decades Later

Long-term study looks at what happened when sugar was scarce

FDA Committee Votes Down Duchenne Drug

Agency staff and drug developer disagree on endpoints

Recommended News For You

In advanced endometrial cancer, immunocheckpoint inhibitor-chemotherapy combination improves overall survival.

Clinical trial is testing whether heavy lifting could combat cancer side effects

Omitting Biopsy After Negative MRI Halves Diagnoses of Insignificant Prostate Cancer

EU Flags Shortage Of Schizophrenia Drug Injections Due to Manufacturing Issues

Drugmaker Pulls Trodelvy's Bladder Cancer Approval

EMA Recommends Generic in Advanced/Metastatic Breast Cancer

A healthier lifestyle after bowel screening shown to prevent bowel cancer

Recommended Articles For You

Reshaping the Battlefield Through Tumor Microenvironment Modulation for Cancer Therapy 

Hematopoietic Microenvironment Rejuvenation Through Cellular Architecture Remodeling 

Neuroendocrine Tumors: Mechanisms of Mortality, Associated Conditions 

Engineered Hematopoietic Cells for Targeted Correction of Abnormal Blood-Cell Production 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Sevabertinib Approved for First-Line Mutated NSCLC

2.

Top 10 questions about breast cancer answered

3.

Inadvertent lung cancer screening results are discussed in a new study.

4.

United States Lung Cancer Screening Rates Remain Low. s. in particular in the South.

5.

Study indicates that exercise can help colon cancer survivors live as long as matched individuals

1.

Red Blood Cell Microparticles: Tiny Warriors Against Bleeding in the Brain

2.

An Analytical and Statistical Journey through Genomic Revolution, Novel Therapeutics, and Future Horizons in Lymphoma 2025

3.

Neoadjuvant Radiotherapy & Endocrine Therapy in ER+ Breast Cancer Treatment

4.

A New Hope: Exploring the Potential of Pegaspargase in Treating Cancer

5.

CA-125 Test: Why It's Important for Women's Health and Early Detection of Ovarian Cancer

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V

2.

Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias

3.

What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?

4.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part II

5.

Breaking Down PALOMA-2: How CDK4/6 Inhibitors Redefined Treatment for HR+/HER2- Metastatic Breast Cancer

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot